T ools for assessing methodological quality or risk of bias in randomized controlled trials (RCTs) and non-randomized studies (NRS) were reviewed. The van Tulder scale and Cochrane's assessment of risk of bias are the two most useful methodological quality evaluation tools for RCTs. Cochrane's tool includes sequence generation, allocation of sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other potential sources of bias. The Cochrane Collaboration Group recommends the Downs and Black instrument and the Newcastle-Ottawa Scale for evaluating the quality of NRS. In conclusion, this study offers useful information to physicians about tools for assessing the quality of evidence in clinical guidelines. Further research is needed to provide an essential core for evidence-based decision making regarding levels and/or grades of recommendations. 특히 국내 문헌 혹은 근거의 대부분이 비무작위 연구
Lim SM et al. (Table 2) . reasons for missing data across intervention groups; • For dichotomous outcome data, the proportion of missing outcomes compared with observed event risk enough to induce clinically relevant bias in intervention effect estimate; • For continuous outcome data, plausible effect size among missing outcomes enough to induce clinically relevant bias in observed effect size; • ' As-treated' analysis done with substantial departure of the intervention received from that assigned at randomization; • Potentially inappropriate application of simple imputation Selective outcome reporting Yes • The study protocol is available and all of the study's pre-specified (primary and secondary) outcomes that are of interest in the review have been reported in the pre-specified way; • The study protocol is not available but it is clear that the published reports include all expected outcomes, including those that were pre-specified No • Not all of the study's pre-specified primary outcomes have been reported;
van Tulder 척도
• One or more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g., subscales) that were not pre-specified; • One or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided, such as an unexpected adverse effect); • One or more outcomes of interest in the review are reported incompletely so that they cannot be entered in a meta-analysis; • The study report fails to include results for a key outcome that would be expected to have been reported for such a study Other potential threats to validity Yes • Had a potential source of bias related to the specific study design used; or
• Stopped early due to some data-dependent process (including a formal-stopping rule); or • Had extreme baseline imbalance; or • Has been claimed to have been fraudulent; or • Had some other problem No • Insufficient information to assess whether an important risk of bias exists; or
• Insufficient rationale or evidence that an identified problem will introduce bias * Minimization may be implemented without a random element, and this is considered to be equivalent to being random. (Table 7A) . 코호트 연구는 코 호트 선택, 코호트 비교가능성, 그리고 결과 평가에 대해 평 가할 수 있다 (Table 7B) . NewcastleOttawa [29] Reish et al. [30] Thomas [31] Zaza et al. [32] 1. Background
평가방법은 각 항목에 대해 근거의 질이 높은 경우 '★'로 표 시하도록 되어 있는데, 선택과 노출/결과에 대한 항목의 경우
• Clear specification of interventions √ √ √ 4. Outcomes
• Clear specification of outcomes √ √ 5. Creation of groups
• Generation of random sequence Reporting: "Yes=1," "No=0" 1. Is the hypothesis/aim/objective of the study clearly described? 2. Are the main outcomes to be measured clearly described in the Introduction or Methods section? 3. Are the characteristics of the patients included in the study clearly described ? 4. Are the interventions of interest clearly described? 5. Are the distributions of principal confounders in each group of subjects to be compared clearly described? "Yes=2," "Partially=1," "No=0" 6. Are the main findings of the study clearly described? 7. Does the study provide estimates of the random variability in the data for the main outcomes? 8. Have all important adverse events that may be a consequence of the intervention been reported? 9. Have the characteristics of patients lost to follow-up been described? 10. Have actual probability values been reported (e.g., 0.035 rather than <0.05) for the main outcomes except where the probability value is less than 0.001?
External validity: "Yes=1," "No=0," "Unable to determine=0" 11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited? 12. Were those subjects who were prepared to participate representative of the entire population from which they were recruited? 13. Were the staff, places, and facilities where the patients were treated, representative of the treatment the majority of patients receive?
Internal validity -bias: "Yes=1," "No=0," "Unable to determine=0" 14. Was an attempt made to blind study subjects to the intervention they have received ? 15. Was an attempt made to blind those measuring the main outcomes of the intervention? 16. If any of the results of the study were based on "ata dredging" was this made clear? 17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and outcome the same for cases and controls? 18. Were the statistical tests used to assess the main outcomes appropriate? 19. Was compliance with the intervention/s reliable? 20. Were the main outcome measures used accurate (valid and reliable)?
Internal validity -confounding (selection bias): "Yes=1," "No=0," "Unable to determine=0" 21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population? 22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of time? 23. Were study subjects randomised to intervention groups? 24. Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable? 25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn? 26. Were losses of patients to follow-up taken into account? Power 27. Did the study have sufficient power to detect a clinically important effect where the probability value for a difference being due to chance is less than 5%? Sample sizes have been calculated to detect a difference of x% and y%.
Size of smallest intervention group
Lim SM et al. Table 7A . Newcastle-Ottawa quality assessment scale: case-control studies [29] NEWCASTLE -OTTAWA QUALITY ASSESSMENT SCALE CASE CONTROL STUDIES Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Exposure categories.
어서 검색된 문헌의 질을
A maximum of two stars can be given for Comparability. Exposure 1) Ascertainment of exposure a) secure record (eg surgical records) ★ b) structured interview where blind to case/control status ★ c) interview not blinded to case/control status d) written self report or medical record only e) no description 2) Same method of ascertainment for cases and controls a) yes ★ b) no 3) Non-response rate a) same rate for both groups ★ b) non respondents described c) rate different and no designation Table 7B . Newcastle-Ottawa quality assessment scale: cohort studies [29] NEWCASTLE -OTTAWA QUALITY ASSESSMENT SCALE COHORT STUDIES Note: A study can be awarded a maximum of one star for each numbered item within the Selection and Outcome categories.
A maximum of two stars can be given for Comparability Selection 1) Representativeness of the exposed cohort a) truly representative of the average _______________ (describe) in the community ★ b) somewhat representative of the average ______________ in the community ★ c) selected group of users eg nurses, volunteers d) no description of the derivation of the cohort 2) Selection of the non exposed cohort a) drawn from the same community as the exposed cohort ★ b) drawn from a different source c) no description of the derivation of the non exposed cohort 3) Ascertainment of exposure a) secure record (eg surgical records) ★ b) structured interview ★ c) written self report d) no description 4) Demonstration that outcome of interest was not present at start of study a) yes ★ b) no
Comparability 1) Comparability of cohorts on the basis of the design or analysis a) study controls for _____________ (select the most important factor) ★ b) study controls for any additional factor ★ (This criteria could be modified to indicate specific control for a second important factor.)
Outcome 1) Assessment of outcome a) independent blind assessment ★ b) record linkage ★ c) self report d) no description 2) Was follow-up long enough for outcomes to occur a) yes (select an adequate follow up period for outcome of interest) ★ b) no 3) Adequacy of follow up of cohorts a) complete follow up -all subjects accounted for ★ b) subjects lost to follow up unlikely to introduce bias -small number lost -> ____ % (select an adequate %) follow up, or description provided of those lost) ★ c) follow up rate < ____% (select an adequate %) and no description of those lost d) no statement
